The first five-year cumulative revenue (2017-2021) is projected to be US$ 66,394.1 Mn, which is expected to increase rather moderately over the latter part of the five-year forecast period. According to report, the insulin delivery systems market is projected to reach a value of over US$ 22,511.8 Mn in 2026 at a CAGR of 7.8% over the forecast period.

Global Insulin Delivery Systems Market: Segmental Snapshot

According to global insulin delivery systems market infographics published on MarketResearch.biz, over 8.0% CAGR by Product.

By-product: The insulin pen segment accounted for highest revenue share contribution as compared to that of the insulin pump, insulin syringe, and others. The insulin pump segment is expected to register a CAGR of over 8.0% between 2017 and 2026.

By distribution channel: The hospitals segment is estimated to register highest CAGR of 7.8% as compared to that of the other end user segments. Also, it is projected to account for a dominant revenue share in the global insulin delivery systems market over the forecast period.

By region: The market in North America accounted for highest revenue share in the global insulin delivery systems market in 2016, and is expected to register a CAGR of over 7.0% between 2017 and 2026.

Global Insulin Delivery Systems Market: Competitive Analysis

The research report on the global insulin delivery systems market includes profiles of some of major companies such as Becton, Dickinson and Company, Eli Lilly and Company, Medtronic plc, Sanofi, F. Hoffmann-La Roche Ltd., Cellnovo Limited, Insulet Corporation, Tandem Diabetes Care, Inc., Companion Medical, Inc., and Copernicus Sp. z o.o.

Source of Infographics: Insulin Delivery System Market Infographics by MarketResearch